QM · rank #15 · 2026-10-23
PACS
NYSE · $7.56B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +217.72% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +27.9% |
| Profit margin Net profit margin, trailing 12 months. | +4.9% |
| Market cap (USD) Size filter: > $500M required. | $7.56B |
| Anchor (recent) Close on 2026-09-23 | $41.05 |
| Anchor (far) Close on 2025-09-23 | $12.92 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
PACS Group operates a fast-growing multi-state post-acute and skilled-nursing platform, with more than 33,400 patients served daily and expansion to 355+ affiliated buildings across 21 states.
Rationale
The name fits a quality_momentum screen because 12-1 momentum is strong, ROE is high at 27.9%, profitability is positive, and recent acquisition-led growth plus raised 2026 guidance reinforce both earnings quality and price strength.
Material risks
- 1Ongoing DOJ investigations and subpoenas into FCA, Anti-Kickback, Medicare billing, COVID-waiver and reimbursement issues could pressure earnings and sentiment if findings turn adverse.
- 2Rapid acquisition-led expansion into new states raises integration, lease, staffing and occupancy execution risk, which could dilute the quality profile if operating discipline slips.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.